which enhances serotonin and noradrenaline release (de Boer, 1996) , and antagonism of serotonin (5-HT) and histamine (H 1 ) receptors (Stahl, 2008; Stahl, Mignon, & Meyer, 2009 ). Inhibition of 5-HT 2C and H 1 receptors may account for the orexigenic effects of mirtazapine (Stahl, 1998) . Reduction in nausea and vomiting observed in cats (Quimby & Lunn, 2013 ) is theorized to be due to antagonism of 5-HT 3 receptors (Stahl, 2008) .
The mirtazapine transdermal ointment used in this study was approved by the Food and Drug Administration (FDA) on May 4, 2018
[New Animal Drug Application 141-481; https://animaldrugsatfda. fda.gov/adafda/app/search/public/document/downloadFoi/3487] for the management of weight loss in cats and has been shown to achieve measurable plasma concentrations of mirtazapine following single and repeat dosing in the cat (Buhles, Quimby, Labelle, & Williams, 2018) . Weight loss and chronic dysrexia in cats can lead to serious complications such as hepatic lipidosis (Valtolina & Favier, 2017) , altered immune function (Valtolina & Favier, 2017) , delayed wound healing (Agnew & Korman, 2014) , and decreased survival time (Finn, Freeman, Rush, & Lee, 2010) . Appetite is considered by owners to be an important aspect of quality of life, and such secondary complications may influence an owner's decision to humanely euthanize their cat (Reynolds et al., 2010) .
Administering oral medication to cats can be challenging.
Topically applied medications have been used in cats due to the ease of dosing compared to orally administered medications (Hill et al., 2015) and can improve owner compliance (Hill et al., 2011) .
The purpose of this study was to evaluate body weight gain in cats treated with mirtazapine transdermal ointment that were experiencing unintended weight loss associated with various underlying diseases.
| MATERIAL S AND ME THODS

| Study design
This was a multi-center, randomized, double-blind, placebocontrolled study in client-owned cats conducted at 20 veterinary sites across the United States. It was conducted according to Good Clinical Practices (FDA Center for Veterinary Medicine (CVM) Guidance 85; VICH GL9). The scientific and ethical validity of the study was reviewed by FDA prior to study conduct (Study protocol KB105, FDA protocol concurrence received on Jan 7, 2016). The protocol was approved by the East Tennessee Clinical Research Institutional Animal Care and Use Committee (IACUC) . All cat owners reviewed and signed informed owner consent forms prior to participation in the study. For the purpose of calculating study power, it was assumed that cats in the mirtazapine group would have an average of a 3% increase in body weight and cats in the placebo group would have an average of a 0% increase in body weight, a common standard deviation of 6%, and a 15% drop-out rate. The study was intended to enroll at least 100 eligible cats in each treatment group and was therefore powered at a 90% level, with a two-way p-value of 0.05, to demonstrate statistical significance of the difference in the mean percent change in body weight between mirtazapine and placebo.
| Inclusion/exclusion criteria
Cats were included in the study if they were ≥1 year of age, had ad libitum access to food and a documented medical history of ≥5% body weight loss without calorie restriction. Treatments (e.g., flea control, vaccinations, etc.) which had no impact on the clinical conditions being investigated were allowed during the study for both treatment groups. Cats receiving diuretics, insulin, and/or ACE inhibitors must have been on a stable regimen at Day 1. Subcutaneous fluid as supportive therapy was permitted during the study; however, it was required that body weight be measured prior to fluid administration if fluid therapy was received on a day of weighing. Systemic corticosteroids were allowed for treating any underlying illness, but the dose and schedule must have not been altered for 14 days prior to Day 1 or during the study. Cats were excluded if they were pregnant or lactating, had a body weight <2.0 kg, had been diagnosed with neoplasia or severe kidney disease (International Renal Interest Society Stage 4 or serum creatinine >5.0 mg/dl), or received any prohibited concurrent medication. Additional medications intended to stimulate appetite or cause weight gain were not allowed for 7 days prior to the study or during the study and included diazepam, oxazepam, phenothiazines, metoclopramide, cyproheptadine, maropitant, and marinol. Additional exclusion criteria included treatment within 30 days of study onset with mirtazapine, monoamine oxidase inhibitors, or other serotonergic drugs. Cats that were not expected to survive the study were also excluded.
| Animal housing and diet
Study cats remained at home with their owners. To minimize environmental factors influencing appetite, the normal environment of each cat was maintained throughout the study (indoors or outdoors and diet). Cats had ad libitum access to food, except for the two-hour period immediately preceding hospital visits on Days 1 and 14. Cats were allowed to be on special diets during the study. The cat's food type (wet, dry, mixed, special, or standard diet) was not altered for 7 days prior to the onset of the study and was maintained through the study completion. and Dry Flo TS. The formulation used in this study was the final commercial formulation and was stable under storage conditions of 25°C/60% relative humidity for at least 30 months which covered the duration of the study. Mirtazapine transdermal ointment and placebo ointment were manufactured at the same facility and under the same conditions. The placebo ointment consisted of the same formulation without the active ingredient, mirtazapine.
| Treatment drug and placebo
| Dosing and application
Cats were randomized 1:1 into mirtazapine or placebo groups. A centralized block randomization was implemented with a block size of four. Cats were enrolled based on the order of presentation to the clinic; the blocking scheme was used to maintain an approximately equal number of cats per treatment arm and was not considered a factor in the statistical model. An independent third-party statistician generated the randomization list. Mirtazapine was dosed at 2 mg/cat (0.1 g of 2% ointment), regardless of body weight. Placebo was dosed at the same volume. Each cat was dosed by applying mirtazapine or placebo ointment topically to the inner surface of the pinna once daily for 14 days according to treatment assignment. A 1.5-inch ribbon of ointment (mirtazapine or placebo) constituting approximately 0.1 g was applied on the pinna and spread over the inner (anterior) surface using a gloved finger. Owners were allowed to alternate ears for dose application. A dosing card was provided to the owner to assist in determining the appropriate ribbon length (Kindred Biosciences, Inc., 2018) . For all doses, the date, dose number, and ear (left or right) treated was recorded in the Owner Diary Dose Log. Compliance with treatment was evaluated via the Owner Diary Dose Log.
| Statistical analysis
Effectiveness was defined as meeting all three of the following criteria: (a) a statistically significant difference between treatment groups (p < 0.05) in mean percent change in body weight (Day 1 to 
| RE SULTS
| Cats
A flow diagram of study enrollment is presented in Figure 1 . The signalment, baseline weight, and underlying condition for the Safety and PP populations are presented in Table 1 . Breed information is presented in Supporting Information Table S1 . Dose of study drug (mg/kg) is presented in Supporting Information Table S2 .
A listing of concurrent medications is presented in Supporting Information
Tables S3 and S4.
| Compliance
Compliance was assessed by owner entries in the Owner Diary Dose Log (see sample in the Supplemental Material). One hundred and sixty-six cats received all doses of study drug, 45 cats missed one dose (23 in the mirtazapine group and 22 in the placebo group), and 14 cats missed two doses (eight in the mirtazapine group and six in the placebo group). Of the 14 cats who missed two doses, three were consecutive missed doses and 11 were nonconsecutive missed doses. Three cats missed three doses (and two cats missed four doses). Cats that missed ≥ 20% of doses of study drug were not included in the PP population for analysis.
| Effectiveness
In the PP population, the mean percent change in body weight from Day 1 to Day 14 was +3.9% in the mirtazapine group and +0.4% in the placebo group (p < 0.0001; Figure 2 , Table 2 ). The effectiveness of mirtazapine versus placebo in cats with and without preexisting kidney disease, those receiving glucocorticoids, and those undergoing treatment for hyperthyroidism was evaluated separately and is presented in Table 3 (Per Protocol Population). Data for the ITT population are provided in Supporting Information Figure S1 ; Tables S5   and S6 . F I G U R E 1 Disposition. Disposition is depicted in this figure. In this study, there were 257 cats screened; 26 were excluded and ultimately 231 were randomized to treatment. The Safety Population consisted of all cats randomized to either treatment group who received at least one dose of study drug. The Intent-to-Treat (ITT) population included all cats randomized and who received at least one dose of study drug and had at least one postbaseline body weight measurement. The Per Protocol (PP) population included all cats completing the study through and including Day 14. One cat with preexisting dental disease underwent dental prophylaxis, and this cat was not included in the effectiveness population [Colour figure can be viewed at wileyonlinelibrary.com] 
Efficacy analysis populations
Randomized to placebo, but withdrawn before study drug administered (n = 1) 
Safety analysis population
| Safety
In the 230 cat Safety Population, no significant difference was seen in the percentage of cats in each group that were reported to have experienced an AE. A summary of AEs that occurred in greater than 5% of cats in the Safety Population is presented in Table 4 . Incidence of behavioral adverse events (vocalization and hyperactivity) in the overall population as well as in subgroups based on weight and presence/absence of kidney disease are presented in Table 5 .
Nine cats discontinued the study early due to a reported AE or serious adverse event including four placebo-treated cats and five mirtazapine-treated cats, regardless of causality to treatment. Eight cats were euthanized due to progression of their underlying disease, and one cat in the placebo group with preexisting cardiac disease, inflammatory bowel disease, and hyperthyroidism died at home. Of the three cats that were euthanized in the mirtazapine group, two had necropsies performed. In both cases, there were multiple findings related to underlying conditions and no causal relationship to mirtazapine was established.
| Clinical pathology
There were significant differences (p < 0.10) in several mean clinical pathology parameters at Day 14 compared to Day 1 (Supporting Information Table S7 ); however, each of these parameters was within the normal laboratory reference range and not considered clinically relevant except for BUN. The mean BUN concentration for the mirtazapine group was slightly above the reference range (LS mean 43.6 mg/dl, reference range 16-37 mg/dl) whereas the mean BUN concentration for the placebo group was within the normal range (LS mean 36.1 mg/dl). There was no significant difference in serum creatinine between mirtazapine-and placebotreated cats. 
TA B L E 1 Study population demographics and baseline characteristics
Preexisting conditions and relevant medical history at enrollment >10% in overall population
Description of condition a
Safety population
Per Protocol population Mirtazapine (n = 115) n (%) 
| D ISCUSS I ON
The mirtazapine transdermal ointment used in this study is FDA approved for the management of weight loss in cats. As a new animal drug, the formulation is produced according to cGMP regulations to ensure quality, strength, purity, and stability. In this double-blind, placebo-controlled study, daily topical mirtazapine ointment applied to the inner pinna of the cat's ear effectively increased body weight within 14 days in client-owned cats experiencing unintended weight loss associated with a variety of underlying diseases.
To be included in this study, cats had to have a clinical history of decreased food consumption and ≥ 5% loss in body weight.
Weight loss of ≥ 5% in a cat with comorbidities is considered clinically relevant and should signal the clinician to evaluate nutrition and health status (Brooks et al., 2014; Laflamme & Hannah, 2005) .
Although few studies have characterized appropriate weight gain in cats, recommendations for intentional weight loss indicate that the loss not exceed 1%-2% of body weight per week and that all changes should be slow and incremental (Brooks et al., 2014; Laflamme & Hannah, 2005) . In this study, population of cats experiencing weight loss associated with various underlying conditions, the 3.9% weight gain observed in cats receiving topical mirtazapine for 14 consecutive days represents significant weight gain, that is, clinically relevant.
Incidence of behavioral AEs of vocalization (including crying
and meowing) and hyperactivity (including pacing, restlessness, and sleeplessness) were significantly more common in mirtazapinetreated cats compared to placebo-treated cats but affected a small number of cats (Table 5 ). In a previous study, treatment with highdose (3.75 mg) oral mirtazapine in healthy young cats was associated with an increase in behavior such as vocalization (Quimby, Gustafson, Samber, & Lunn, 2011b) . Additionally, a previous retrospective study of orally administered mirtazapine demonstrated significant behavioral adverse effects with accidental administration of an entire 15 mg tablet (Ferguson et al., 2016) . Conversely, the same mirtazapine transdermal ointment as studied here reported no significant change in animal behavior when applied topically to the inner pinna at approximately 5-10X the recommended dose (range 15.8-22.0 mg) to healthy cats for 28 days, (Avenatti, Buhles, Quimby, Labelle, & Poole, 2017) . For cats experiencing either reduced elimination due to disease state or behavioral effects, dose alteration may be considered (Quimby & Lunn, 2013; Quimby et al., 2017) .
Cats weighing both ≤4 kg and >4 kg had significant body weight gain when treated with mirtazapine compared to placebo despite a wide range in starting body weights (2.1-9.2 kg). No significant difference was seen when incidence of behavioral AEs of vocalization and hyperactivity were compared between mirtazapine and placebo groups in the population of cats <4 kg (Table 5 ). These findings support the use of 2 mg/cat of mirtazapine transdermal ointment for all cats, irrespective of body weight at the start of treatment.
Cats with kidney disease have been shown to have delayed clearance of oral mirtazapine (Quimby, Gustafson, & Lunn, 2011a) .
In the present study, approximately 50% of cats in the mirtazapine group and 60% of cats in the placebo group were diagnosed with preexisting kidney disease at the discretion of the clinical investigator. The criteria used to diagnose renal disease were not specified by the study protocol and is a limitation of the study. Both populations of cats (those with and without kidney disease) demonstrated significant body weight gain with the application of topical mirtazapine compared to placebo-treated cats (Table 3 and Supporting   Information Table S6 ). This study was not designed to assess the effect of clearance by the kidneys on the safety of mirtazapine in cats with suspected kidney disease. However, no significant difference was seen when incidence of behavioral AEs of vocalization and hyperactivity were compared between mirtazapine and placebo groups in the population of cats with kidney disease (Table 5) .
Mirtazapine transdermal ointment applied topically at 2 mg/cat was well tolerated both locally and systemically in this study. The differences found in clinical pathology parameters between placebo and mirtazapine-treated cats in clinical pathology parameters were not considered clinically relevant. The elevated BUN levels observed in the mirtazapine-treated cats could be explained by the increased incidence of kidney disease as diagnosed by the clinical investigators in the mirtazapine group at the time of enrollment. The most common finding in both mirtazapine and placebo groups was erythema of the pinna. Other signs of irritation at the site of application included crusting and scabbing which were also more frequent in the control group.
In the diverse clinical population of cats with unintended weight loss seen in veterinary practices, there can be a variety of concurrent medications administered for underlying diseases. While this study was not designed to assess drug interactions, use of concurrent medications (including glucocorticoids and antithyroid medications)
did not appear to impact the safety or efficacy of mirtazapine transdermal ointment (Table 3 ).
The inner surface of the pinna was chosen as the application site due to ease of application. It is less haired, highly vascular, and thinner than other anatomical locations which may improve transdermal absorption (Hill et al., 2015) and is a common site of application for other topical ointments in the cat. (Bennett, Papich, Hoenig, Fettman, & Lappin, 2005; Benson et al., 2017; Ciribassi et al., 2003; Hill et al., 2011; Mealey et al., 2004; Miller, Schick, Boothe, & Lewis, 2014 ).
The mirtazapine transdermal formulation used in this study was supplied in a 5 g tube and the dose was a 1.5-inch ribbon (2 mg mirtazapine) per cat, which is approximately 0.1 ml. As with any topical medication, there is a possible risk of exposure to family members or other individuals handling the cat. Visual inspection to determine how quickly the ointment was absorbed was not performed in this study. However, in a previous study conducted to evaluate dislodgeable residues of the mirtazapine transdermal ointment following repeated application, it was found that for body petting, dislodgeable residues were very low (lower than significant human mirtazapine exposure, but should be avoided for 2 hr following application.
Although cats can groom their ears, they cannot directly lick their inner pinna which may allow the ointment to remain in contact with the skin for a longer period, thus improving absorption and minimizing potential oral ingestion of the medication.
Pharmacokinetic studies have been performed with this formulation of mirtazapine ointment in cats with e-collars and have demonstrated transdermal absorption without oral ingestion (Buhles et al., 2018) . However, as cats in the present study did not wear e-collars, some degree of oral ingestion may have occurred in addition to transdermal absorption.
In order to be included in PP population, cats had to have 80%
compliance. For cats that missed 1-2 doses, the effect on serum concentrations is unknown as the pharmacokinetic/pharmacodynamic relationship for transdermal mirtazapine has not been clearly established and clinical effectiveness may not be linear to plasma concentrations. A statistically significant increase in weight was still seen in the mirtazapine group regardless of an occasional missed dose in a small number of cats.
It is expected that cats with chronic disease associated with dysrexia will need therapy beyond 14 days to maintain body weight.
A limitation of this study is that it did not evaluate the long-term In this study, mirtazapine transdermal ointment applied topically to the inner surface of the pinna was effective for increasing body weight following 14 days of daily treatment in cats with unintended weight loss associated with a variety of underlying diseases. Topical application of mirtazapine transdermal ointment was well tolerated both locally and systemically.
